Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia.

accelerated phase basophilia clinical prognosis leukemic transformation primary myelofibrosis

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2019
Historique:
received: 07 06 2019
accepted: 21 08 2019
entrez: 27 9 2019
pubmed: 27 9 2019
medline: 27 9 2019
Statut: epublish

Résumé

Basophils are white blood cells that play an important role in the human immune system. These cells physiologically increase in number in immune response to certain allergies, chronic inflammation, and parasitic infections. Basophils are also a significant indicator for the presence of certain malignancies such as chronic myeloproliferative neoplasms and acute myeloid leukemia. In the current manuscript we present a statistically significant correlation between persistent basophilia in primary myelofibrosis (PMF) and the risk for the subsequent development of acute myeloid leukemia. We have retrospectively identified in the files of the Department of Hematology, Ion Chiricuta Clinical Cancer Center in Cluj Napoca, Romania 623 consecutive patients diagnosed with AML over a period spanning from 2008 to 2018. We afterwards identified 32 patients with AML diagnosis following a previous diagnosis of myelofibrosis (either post-PV, post-ET, or post-PMF). All the patients were diagnosed according to the WHO criteria. We subsequently established a control group consisting of 32 patients with underlying BCR-ABL-negative MPN who did not develop AML (AML-negative group). Following this, we assessed whether the AML-negative patients from our control group also had a persistent (>3 months) absolute basophilia. When comparing both groups of patients with myelofibrosis, the group with subsequent AML development and the one without AML, the follow-up did not present statistically significant differences between the two groups. In the univariate analysis, patients who progressed to AML had more frequently basophilia, longer basophilia duration, higher pre-therapy absolute, and relative basophil count and presented more frequently calreticulin (CALR) mutations. In the current study, we emphasize the need for a closer clinical monitoring for chronic MPNs with marked basophilia, with an important potential clinical impact.

Identifiants

pubmed: 31555600
doi: 10.3389/fonc.2019.00872
pmc: PMC6742718
doi:

Types de publication

Journal Article

Langues

eng

Pagination

872

Références

N Engl J Med. 2000 May 4;342(18):1350-8
pubmed: 10793168
Blood. 2000 Sep 15;96(6):2022-36
pubmed: 10979943
Blood. 1992 Aug 1;80(3):634-41
pubmed: 1379084
Chem Immunol Allergy. 2006;90:141-156
pubmed: 16210908
Blood. 2007 Aug 1;110(3):986-93
pubmed: 17473062
Cancer. 2008 Jun 15;112(12):2726-32
pubmed: 18404742
Blood. 2009 Feb 26;113(9):2022-7
pubmed: 19047681
J Immunol. 2009 Mar 1;182(5):2835-41
pubmed: 19234178
Leuk Res. 2010 Jun;34(6):821-3
pubmed: 19819015
Blood. 2010 Apr 8;115(14):2891-900
pubmed: 20008300
Blood. 2010 Jun 3;115(22):4350-5
pubmed: 20308601
Mod Pathol. 2013 Feb;26(2):204-12
pubmed: 23018876
Am J Hematol. 2016 Feb;91(2):E8
pubmed: 26572775
Leukemia. 2017 Apr;31(4):788-797
pubmed: 28090091
J Cell Physiol. 2018 Jan;233(1):422-433
pubmed: 28294327
Int J Lab Hematol. 2017 Aug;39(4):409-417
pubmed: 28318095
Oncotarget. 2017 Oct 6;8(60):101735-101744
pubmed: 29254200
Blood Cancer J. 2018 Feb 9;8(2):15
pubmed: 29426921

Auteurs

Jerome Dobrowolski (J)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Sergiu Pasca (S)

Department of Hematology, Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Patric Teodorescu (P)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Cristina Selicean (C)

Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Ioana Rus (I)

Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Mihnea Zdrenghea (M)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Anca Bojan (A)

Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Adrian Trifa (A)

Department of Genetics, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Bogdan Fetica (B)

Department of Pathology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Bobe Petrushev (B)

Department of Pathology, Regional Institute for Gastroenterology and Hepatology, Cluj Napoca, Romania.

Ana-Maria Rosu (AM)

Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Ioana Berindan-Neagoe (I)

Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.

Ciprian Tomuleasa (C)

Department of Hematology, Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Delia Dima (D)

Department of Hematology, Ion Chiricuta Clinical Cancer Center, Cluj Napoca, Romania.

Classifications MeSH